Peptide Library

FDA-approved

Digestive & weight

Lutetium Lu-177 dotatate

Evidence

FDA approved

Class

Radiolabeled somatostatin analog (therapy)

/

Lutetium Lu-177 dotatate

KEY TAKEAWAY

Lutetium Lu 177 dotatate is a somatostatin-receptor-binding peptide carrying a radioactive lutetium atom. It is sold as Lutathera. The FDA approved Lutathera in 2018 for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, and later for adolescents aged 12 and older.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Radiolabeled somatostatin analog (therapy)

Approved for

Neuroendocrine tumors of the gut and pancreas that carry somatostatin receptors

Key fact

The FDA approved Lutathera in 2018 for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, and later for adolescents aged 12 and older.

Route

Intravenous infusion in a series of treatments

Evidence strength

FDA approved

What it is

What it is

Lutetium Lu 177 dotatate is a somatostatin-receptor-binding peptide carrying a radioactive lutetium atom. It is sold as Lutathera.

How it works

How it works

The peptide carries radiation directly to tumor cells that have somatostatin receptors, and the radiation damages them while sparing most other tissue.

Regulatory status

Regulatory status

The FDA approved Lutathera in 2018 for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, and later for adolescents aged 12 and older.

What it is used for

What it is used for

Neuroendocrine tumors of the gut and pancreas that carry somatostatin receptors.

Side effects and risks

Side effects and risks

Nausea, vomiting, low blood counts and kidney effects are the main concerns. Because it is radioactive, specific radiation-safety precautions apply.

Citations

Citations

U.S. FDA prescribing information for Lutetium Lu-177 dotatate. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo